Introduction {#S0001}
============

Uncovering interactions between environmental factors, such as diet and lifestyle, and metabolic pathways is crucial to elucidate aging mechanisms. Some of the most promising candidate genes appear to be involved in regulatory pathways such as stress resistance, immune/inflammatory response, insulin signalling, or cardiovascular function.[@CIT0001] The survival and maintenance of the internal environment in many cells depend largely on their ability to respond to cellular stressors. In yeast, it has been demonstrated that Nat4 (the yeast ortholog of hNAA40) levels are mediated and controlled by caloric restriction (CR) and that one of the main effects of decreasing Nat4 levels is increasing the lifespan of yeast cells through a pathway that upregulates the host's stress-response genes, PNC1 (the yeast ortholog of nicotinamide phosphoribosyltransferase (NAMPT)), Glycogen phosphorylase (GPH1), Hexokinase (HXK), 1,4-alpha-glucan-branching enzyme (GLC3), Trehalose-phosphatase (TPS2), Glycogen \[starch\] synthase isoform 1 (GSY1), and Neutral trehalase (NTH1).[@CIT0002] Of these genes, PNC1 is known to encode a nicotinamidase that lowers the accumulation of nicotinamide (Nam) intracellularly which would result in stimulating the activity of Sir2 (the yeast ortholog of Sirtuins)[@CIT0003] and thus enhancing the cell's response to stressors. NAMPT is the rate-limiting enzyme in mammalian NAD synthesis, catalyzing nicotinamide mononucleotide (NMN) formation from Nam and 5-phosphoribosyl 1-pyrophosphate (PRPP). Thus, NAMPT is thought to be involved in many important biological processes, including metabolism, stress response, and aging.

It can be assumed that hNAA40 (human ortholog of Nat4) is similarly controlled and has similar effects in humans. Accordingly, high caloric intake, the abundance of macronutrients in the body, and high amounts of body fat could increase the levels of hNAA40 resulting in the reduction of stress-response proteins, NAMPT and Sirtuins. This would result in reduced cell's response to stressors and decreased life span. Increasing cellular lifespan can be helpful in age-related diseases such as Alzheimer's or cancer treatment where increasing longevity and activity of immune cells may boost their efficacy in killing tumor cells.[@CIT0004] Histone modification changes represent an attractive model through which several environmental signals, such as diet, could play a pivotal role in regulating cell lifespan.[@CIT0003] Several reports show that diet manipulation, such as CR, extends the cellular lifespan and hinders age-related chronic diseases of many species, such as rats, fish, mites, and yeast.[@CIT0005] CR is also known to regulate insulin secretion and prevents insulin resistance. In contrast, obesity, a state of overeating, is usually associated with inappropriate secretion of insulin and is considered as a risk factor for T2DM, which results in hyperglycemia, insulin resistance, and hyperinsulinemia.[@CIT0006],[@CIT0007] Therefore, CR is considered the most conserved and well‐studied extracellular intervention that prolongs lifespan.[@CIT0008],[@CIT0009]

Histone modification changes represent an attractive target of therapeutic intervention in relation to aging. The use of PBMC may provide a useful tool to study human aging as it has been accepted to represent changes in the whole body[@CIT0010] and thus has been suggested to represent the biological processes occurring in the body relevant to aging and longevity. Therefore, this study was conducted to determine the differential expression of hNaa40 and its associated stress-response genes, NAMPT and SIRT-1, in PBMC isolated from lean, obese, and drug-Naïve obese T2DM humans. We also examined their levels in T2DM on Metformin which has anti-aging properties and has been shown to be a direct SIRT1-activating compound.[@CIT0011] In addition, the association between the source of substrates for energy production and the expression levels of hNAA40, NAMPT, and SIRT-1 in PBMC was examined following a caloric intake of 300 kcalories of glucose or Whey proteins or lipids.

Materials and Methods {#S0002}
=====================

Subjects {#S0002-S2001}
--------

### Lean/Obese/T2DM/T2DM+Metformin Subjects {#S0002-S2001-S3001}

Fasting blood samples were obtained from 30 lean adult volunteers of normal weight, 30 obese adult volunteers, 20 drug-naïve obese T2DM newly diagnosed volunteers, and 30 obese T2DM on Metformin volunteers were recruited for the study ([Table 1](#T0001){ref-type="table"}). The majority of T2DM on Metformin subjects were on Metformin for at least 9 months and up to 15 years. Most of the subjects on Metformin regiments comprised dosages which varied from 1000 to 2000 mg, 5 had dosages ranging from 100 to 500 daily, and 3 had dosages ranging from 3000 to 4500 mg daily. Five T2DM on Metformin subjects were on insulin therapy as well. The study has been approved by the Institutional Review Board (IRB; approval no. SP17/380/R) of King Abdullah International Medical Research Center (KAIMRC) and all subjects gave their written informed consent.Table 1Demographic Data of the Subjected Participated in the Study. Results are Presented as Mean ± S.E.MGroupGenderAge (Years)BMI kg/m^2^Glucose (mmol/L)Hb~A1c~ (%)Insulin (µU/mL)LDL (mmol/L)HDL (mmol/L)Triglycerides (mmol/L)Lean18M, 12F25.7 ± 1.123.0 ± 0.35.1 ± 0.15.8 ± 0.104.8 ± 0.602.54 ± 0.261.35 ± 0.040.83 ± 0.09Obese11M, 19F35.1 ± 2.339.1 ± 1.7\*5.4 ± 0.15.6 ± 0.2510.0 ± 1.5\*3.04 ± 0.161.18 ± 0.051.22 ± 0.12T2DM15M, 5F48.4 ± 3.0\*^σ^32.5 ± 1.9\*10.0 ± 1.1\*^σ^8.0 ± 0.62\*^σ^7.5 ± 2.6\*3.53 ± 0.19\*1.02 ± 0.05\*^δ^1.97 ± 0.23\*^δ^T2DM + Metformin12M, 18F47.1 ± 2.0\*^σ^40.5 ± 1.5\*10.0 ± 0.8\*^σ^8.7 ± 0.35\*^σ^7.8 ± 1.5\*2.60 ± 0.17^σ^0.99 ± 0.04\*^δ^1.56 ± 0.16\*[^1]

### Caloric (300 Kcal) Intake Study {#S0002-S2001-S3002}

Thirty-six normal healthy adult volunteers were recruited into the study. All were normotensive, had a normal lipid profile, normal renal and liver function tests, and were not on any medications. Subjects were randomly assigned to three different groups; each received one type of macronutrient (Glucose or Whey proteins or lipids). Following an overnight fast, a baseline blood sample was taken. Subjects were then given either 300 kcalories of glucose (NERL Trutol 75) or lipids (90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate) or protein (Isopure unflavored Whey proteins isolate (The Isopure Company, California, USA) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose) solution over 5 mins. Cream and protein preparations were diluted with water up to 300 mL solutions. Blood samples were then obtained at 1, 2, and 3 hrs after the macronutrient intake. Subjects, either 1 week before or after the macronutrient challenge, were given 300 mL of water to drink in the fasting state. Blood samples were obtained before and at 1, 2, and 3 hrs after water intake as well. Each subject served as his/her own control. The study was approved by the IRB of King Abdulaziz Medical City. Subjects gave their written informed consent.

Isolation of PBMC {#S0002-S2002}
-----------------

Blood was collected in EDTA containing vacutainers. Blood was carefully layered over 15 mL of Ficol-Hypaque (50 mL Leucosep Tubes, Greiner Bio-One North America Inc, North Carolina, USA) following dilution with an equal volume of Phosphate Buffered Saline (PBS). Tubes were then centrifuged at 450 xg, in a swing out rotor for 30 mins at 22°C and the PBMC layer was harvested with a pipette. PBMC were repeatedly washed with PBS. Fifty microliters of Qiagen RNALater were added to the pellet and samples were then frozen at −80ºC.

Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) Analysis {#S0002-S2003}
-------------------------------------------------------------------

Total RNA was isolated using the Ambion Aqueous kit (Ambion). All isolated RNA samples were treated with DNase I to remove contaminating genomic DNA. The quality and quantity of the isolated RNA were determined using Agilent Bioanalyzer 2100. One μg of total RNA was reverse-transcribed using first-strand cDNA synthesis Kit (Millipore, USA) followed by RT-qPCR. RT-qPCR was performed with a 7900HT Fast Real-Time PCR System (Applied Biosystems, USA), using 2 µL cDNA, 10 µL 2X Sybergreen Master mix (150 mM Tris, pH 9.2, 40 mM (NH~4~)~2~SO~4~, 5 mM MgCl~2~, 0.02% Tween-20, 0.4 mM dNTPs, 1.25 Units Taq Polymerase, 1X Sybergreen) and 0.5 µL of 20 μM gene-specific primers ([Table 2](#T0002){ref-type="table"}). All primers were purchased from Bio-Basic Canada Inc. (Ontario, Canada). The specificity and size of the PCR products were tested by adding a melt curve at the end of the amplifications, analysis on a 2% agarose gel of the bands. Amplicon Bands were isolated and sequenced. The reaction protocol consisted of one activation cycle of 50°C for 2 mins followed by 95°C for 15 s. Thereafter, 40 cycles of denaturation at 95°C for 15 s, and at 60°C annealing/extension for 2 mins were performed. Although normalization to Cyclophilin A, RPL13, and GAPDH showed similar trends, all values were normalized to Cyclophilin A. Results were calculated using Q-Gene Core module 1.2.[@CIT0012]Table 2Primer Sequences for All Primers Used in RT-qPCRPrimerSense (5'→3')Anti Sense (5'→3')Accession NumberhNAA40ACATCCATCTTTCTCCACTTCCTCCCAAAGTGCTGGGATTACNM_024771.3NAMPTCGGCAGAAGCCGAGTTCAAGCTTGTGTTGGGTGGATATTGTTNM_005746.3SIRT-1GCAGATTAGTAGGCGGCTTGTCTGGCATGTCCCACTATCANM_012238.5GAPDHTGCACCACCAACTGCTTAGCGGCATGGACTGTGGTCATGAGNM_002046.7RPL13AACAAGTTGAAGTACCTGGCTTTCTGGTTTTGTGGGGCAGCATANM_000977.3Cyclophilin ACCCACCGTGTTCTTCGACATTTTCTGCTGTCTTTGGGACCT TNM_021130.4

Statistical Analysis {#S0002-S2004}
--------------------

Statistical analysis was carried out using SigmaStat software ver. 3.0 (Jandel Scientific, San Rafael, CA). Normalized mRNA expression was calculated for RT-qPCR results and analysis was carried out using one-way ANOVA on Ranks followed by Dunn's test for pairwise comparisons, and comparison against the lean group was used to compare data for lean, obese, T2DM, and T2DM with Metformin study. One-way repeated measures ANOVA on Ranks test was used for caloric intake challenge study. Two-factor ANOVA was used to evaluate the interaction between treatment (water vs caloric intake) and time. *P*-value \< 0.05 was used to assess significance for all statistical analyses. Results are presented as mean ± S.E.M.

Results {#S0003}
=======

Demographic Data of Subjects {#S0003-S2001}
----------------------------

There were significant differences in the age among the four groups included in the study ([Table 1](#T0001){ref-type="table"}). However, there was no significant correlation between the expression levels of hNAA40, nor NAMPT nor SIRT-1 and age. On the other hand, there were no significant differences in age, BMI, glucose, lipid profile, HbA~1c~, and insulin between T2DM and T2DM on Metformin ([Table 1](#T0001){ref-type="table"}).

mRNA Expression of hNAA40, NAMPT, and SIRT-1 in PBMC of Lean, Obese, T2DM, and T2DM on Metformin {#S0003-S2002}
------------------------------------------------------------------------------------------------

There was a significant increase in mRNA expression of hNAA40 in T2DM when compared to lean and obese subjects. T2DM on Metformin subjects had lower mRNA expression of hNAA40 PBMC when compared to T2DM ([Figure 1A](#F0001){ref-type="fig"}, *P\<0.05*). Similarly, NAMPT expression was significantly lower in PBMC of T2DM ([Figure 1B](#F0001){ref-type="fig"}, *P\<0.05*) when compared to normal lean and obese subjects and Metformin treatment reverted NAMPT expression levels to normal levels. SIRT-1 expression in PBMC of T2DM was also significantly inhibited ([Figure 1C](#F0001){ref-type="fig"}, *P\<0.05*) when compared to lean and obese subjected. T2DM on Metformin subjects had similar mRNA expression of SIRT-1 in PBMC of lean and obese subjects.Figure 1mRNA expression in PBMC of lean, obese, T2DM, and T2DM on Metformin of (**A**) hNAA40; (**B**) NAMPT; and (**C**) SIRT-1. Results are presented as Mean ± S.E.M. \**P*\<0.05 vs lean subjects; ^δ^*P*\<0.05 vs obese; ^σ^*P*\<0.05 vs T2DM.

mRNA Expression of hNAA40, NAMPT, and SIRT-1 in PBMC Following Macronutrient Intake {#S0003-S2003}
-----------------------------------------------------------------------------------

Caloric intake (300 kcal) of either glucose or proteins or lipids in normal volunteers changed insulin and blood glucose significantly when compared to water intake ([Table 3](#T0003){ref-type="table"}). Whey protein intake increased insulin concentrations at 1--3 hrs while glucose intake increased insulin concentrations at 1 and 2 hrs (\**P*\<0.05; [Table 3](#T0003){ref-type="table"}). Lipid intake did not change insulin concentrations significantly. On the other hand, Whey protein intake decreased blood glucose significantly at 1, 2, and 3 hrs when compared to water intake while glucose concentrations decreased at 2 and 3 hrs following glucose or lipid intake (\**P*\<0.05; [Table 3](#T0003){ref-type="table"}). Glucose intake resulted in a significant increase in mRNA expression of hNAA40 in PBMC at 1 hr and decreased significantly at 3 hrs post intake (\**P*\<0.05; [Figure 2A](#F0002){ref-type="fig"}). Lipid intake resulted in an increase in mRNA expression of hNAA40 in PBMC at 2 hr post intake when compared to water intake (\**P*\<0.05; [Figure 2A](#F0002){ref-type="fig"}) and returned to normal levels at 3 hrs. Neither glucose nor lipids intake resulted in a significant change in NAMPT or SIRT-1 expression in PBMC ([Figure 2B](#F0002){ref-type="fig"} and C). Whey proteins, on the other hand, resulted in significantly lower mRNA expression of NAMPT in PBMC at 3 hrs post protein intake when compared to the baseline expression levels or water intake ([Figure 2B](#F0002){ref-type="fig"}). Whey protein intake did not alter expression levels of SIRT-1 in PBMC significantly.Table 3Demographic Data of the Subjects Participated in the Study. Results are Presented as Mean ± S.E.MCaloric IntakeGenderAge (Years)BMI kg/m^2^Glucose-0hr (mmol/L)Glucose-1hr (mmol/L)Glucose-2hr (mmol/L)Glucose-3hr (mmol/L)Insulin-0hr (µU/mL)Insulin-1hr (µU/mL)Insulin-2hr (µU/mL)Insulin-3hr (µU/mL)Glucose11M, 1F21.6 ± 0.2921.5 ± 0.594.9 ± 0.115.1 ± 0.474.3 ± 0.95\*3.9 ± 0.23\*5.7 ± 0.7336.1 ± 6.62\*27.7 ± 7.83\*8.2 ± 3.22Lipids12M21.3 ± 0.2322.0 ± 0.464.9 ± 0.14.6 ± 0.114.5 ± 0.10\*4.6 ± 0.10\*7.5 ± 1.129.3 ± 1.617.4 ± 1.344.8 ± 0.89Whey Proteins12M21.4 ± 0.4022.4 ± 0.594.9 ± 0.154.1 ± 0.13\*4.4 ± 0.13\*4.4 ± 0.12\*8.1 ± 0.8328.7 ± 3.76\*22.9 ± 2.87\*18.3 ± 2.31\*Water35M, 1F21.4 ± 0.1822.0 ± 0.554.9 ± 0.064.9 ± 0.184.8 ± 0.104.8 ± 0.105.6 ± 0.395.4 ± 0.545.6 ± 0.565.6 ± 0.71[^2] Figure 2hNAA40, NAMPT, and SIRT-1 mRNA expression levels in PBMC following (**A**) glucose; (**B**), Whey proteins; and (**C**) lipids at 0, 1, 2, and 3 hrs post-caloric challenge. Results are presented as Mean ± S.E.M. \**P*\<0.05 vs water intake; n=12 per group.

Discussion {#S0004}
==========

The use of PBMC as a tool to study human aging has been proposed to be a useful tool to represent changes in the whole body.[@CIT0010] Increased age-associated changes in gene expression of PBMC have been reported, including increased capacity for apoptosis (Bcl-2 homologous antagonist/killer; *BAK1*), cell cycle regulation (Cyclin-dependent kinase inhibitor 1B; *CDKN1B*), metabolic process (Alpha-2-macroglobulin receptor-associated protein; *LRPAP1*), insulin action (Cation-independent mannose-6-phosphate receptor; *IGF2R*), and increased immune and inflammatory response (Interleukin-27 receptor subunit alpha; *IL27RA*). On the other hand, response to stress (Heat shock cognate 71 kDa protein; *HSPA8*), damage stimulus (X-ray repair cross-complementing protein 6; *XRCC6*), and chromatin remodeling (TERF1-interacting nuclear factor 2; *TINF2*) pathways have been shown to be downregulated in PBMC of old people.[@CIT0001] Aging is associated with overactive immune cells that contribute to autoimmune diseases and downregulation of certain metabolic pathways which increase the risk of infection. This process is known as immunosenescence and is related to mitochondrial function and energy balance.[@CIT0013] NAD^+^ levels markedly decline with age, creating an energy deficit that decreases the body's ability to retain key functions.[@CIT0014] Intracellular levels of NAD^+^ regulate immune and inflammatory pathways, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα).[@CIT0015],[@CIT0016] The rate-limiting step within the NAD^+^ salvage pathway required for converting nicotinamide to NAD^+^ is catalyzed by NAMPT which has been recently labeled as a novel mediator of innate immunity. The silencing of NAMPT expression in monocytes decreased activation and infiltration of monocytes/macrophages and neutrophils in arthritic joints. The decreased monocyte activation was associated with reduced IL-6 production, Th17 cells, and autoantibody titers.[@CIT0017] On the other hand, NAMPT upregulation blocked macrophage apoptosis by activating IL-6 and the prosurvival signal transducer and activator of transcription 3 (STAT3).[@CIT0018] However, the ability of NAMPT to trigger IL-6/STAT3 cell survival pathway did not depend on the presence of nicotinamide and was not blocked by the NAMPT enzyme inhibitor FK866.[@CIT0018] Thus, inhibition of NAMPT expression in PBMC and the higher expression levels of IL-6 previously reported[@CIT0019] in our study support the notion that these pathways are regulated independently.

Endothelial dysfunction is a characteristic of aging‐related vascular disease and is worsened during diabetes. Overexpression of NAMPT increased proliferation and extended replicative lifespan and did so preferentially during glucose overload. Additionally, upregulation of NAMPT in endothelial cells delayed markers of senescence and oxidative stress in high glucose and tube formation were more extensive and glucose-resistant.[@CIT0020] Obesity and T2DM are both associated with insulin resistance and hyperinsulinemia while T2DM is associated with hyperglycemia as well. Since hNAA40, NAMPT, and SIRT-1 expression in PBMC from T2DM were modulated significantly only in T2DM, this suggests that chronic hyperglycemia could be the modulator of these proteins. Although glucose intake induced hNAA40 in PBMC of lean subjects, there was no change in the expression of NAMPT and SIRT-1. Chronic hyperglycemia may be required to modulate NAMPT and SIRT-1. Moreover, the anti-inflammatory effect of insulin,[@CIT0021] stimulated by glucose intake, could inhibit this pathway. Glucose intake in normal subjects induced inflammatory mediators expression in PBMC[@CIT0022] while insulin infusion reduced expression of these inflammatory mediators in PBMC.[@CIT0023] Whey protein intake did not alter the expression levels of hNAA40 as with either glucose or lipid intake. Whey proteins intake induced high levels of insulin secretion that persisted for more than 3 hrs.[@CIT0024] This was associated with a lack of hNAA40 expression level changes and inhibition of NAMPT at 3 hrs. Further studies are needed to examine the insulin modulatory effect of this pathway which may play a role in inflammaging and age-related inflammatory conditions.

Synthesis of NAD^+^ by NAMPT has been shown to be highly sensitive to nutritional changes in adipose tissue. Mice-fed hyper-calorific diets have decreased NAD^+^ levels, primarily as a result of a reduction in NAMPT.[@CIT0025],[@CIT0026] In addition, circulating extracellular-secreted form of NAMPT (eNAMPT), also known as pre-B cell colony-enhancing factor or visfatin, has been reported to be associated with several metabolic and inflammatory disorders such as obesity.[@CIT0027] However, the correlation of plasma eNAMPT levels in obesity and other metabolic disorders still unclear. eNAMPT was not lowered following Metformin treatment, low caloric diets or after gastric surgery in obese patients.[@CIT0028] The lack of correlation could be attributed to the lack of eNAMPT plasma assay sensitivity.[@CIT0029] In our study, Metformin lowered cellular NAMPT expression in PBMC in addition to SIRT-1. Metformin has been proposed to operate as an agonist of SIRT-1.[@CIT0011] Through activation of SIRT-1, whole-body insulin resistance is prevented by increased Adiponectin release. SIRT-1 also inhibits the activation of Peroxisome proliferator-activated receptor-γ (PPARγ)-dependent insulin-resistance genes. Whether Metformin exerts its effect on NAMPT-SIRT-1- PPARγ pathway by modulating hNAA40 is a possibility and requires further investigation.

Human primary monocytes comprise a heterogeneous population that can be classiﬁed into three subsets based on CD14 and CD16 expression.[@CIT0030],[@CIT0031] A dichotomy has been proposed for macrophage activation: classic (M1) vs alternative (M2). The proinflammatory and phagocytic M1 macrophages are classically activated, typically by IFN-γ or lipopolysaccharide (LPS), whereas M2 macrophages decrease inflammation and encourage tissue repair. The highly pro-inflammatory nature of the non-classical monocytes could be a manifestation of the senescence-associated secretory phenotype (SASP). Interestingly, an accumulation of the non-classical monocytes, in conjunction with higher levels of plasma TNFα and interleukin-8 (IL-8), has been observed in the elderly.[@CIT0032] Our previous study has shown that PBMC from T2DM subjects have increased expression of IL-6, inducible nitric oxide synthase (iNOS), TNFα, CD36, and CD206 and reduced expression of CD11b, CD11c, CD169, and CD163 (19). Other studies have demonstrated an increased inflammatory state in obesity and T2DM.[@CIT0033]--[@CIT0035] Similarly, caloric intake has been shown to induce an acute inflammatory response in PBMC of healthy subjects[@CIT0022],[@CIT0036],[@CIT0037] while insulin infusion reduced inflammation.[@CIT0023],[@CIT0038] These factors may contribute to inflammaging and age-related inflammatory conditions, such as atherosclerosis observed in T2DM. In this study, PBMC present in T2DM has increased hNAA40 and a decreased NAMPT and SIRT-1 expression. These data suggest that PBMC are senescent cells since NAMPT and SIRT-1 expression is inhibited. Interestingly, caloric restriction has been shown to reduce inflammation and oxidative stress and results in prolonged lifespan.[@CIT0005],[@CIT0039]--[@CIT0041] Metformin, on the other hand, reduced the expression of hNAA40 and reverted the expression levels of NAMPT and SIRT-1 in PBMC to normal levels. Metformin has been shown previously to reduce caloric intake.[@CIT0042] In addition, Metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance, and atherogenic dyslipidemia but also has a direct anti-inflammatory action.[@CIT0043]--[@CIT0045] These effects could explain the modulatory effect of Metformin on hNAA40/NAMPT/SIRT-1 pathway ([Figure 3](#F0003){ref-type="fig"}) but do not exclude a direct effect of Metformin on hNAA40/NAMPT/SIRT-1 pathway. Further studies are needed to explore this effect.Figure 3A proposed mechanism by which Metformin could be exerting its anti-aging properties. Insulin resistance and chronic food intake may lead to an increased inflammatory state present in T2DM which results in an increase in hNAA40 and reduction in NAMPT and SIRT-1. Metformin could be exerting its effect by reducing caloric intake, insulin resistance, and inflammation.
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[^1]: **Notes:** \**P\<*0.05 vs lean subjects; ^σ^*P*\<0.05 vs obese; ^δ^*P*\<0.05 vs T2DM.

[^2]: **Note:** \**P*\<0.05 vs baseline value (0 hr post-caloric challenge).
